Head-to-head · Cost-Efficiency Index
CoreAge Rx vs VevaRX
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
CoreAge Rx
Anyone optimizing for real value — a transparent flat price you can model for a full year, nationwide, without a bait-and-switch.
Visit CoreAge RxVevaRX
Readers in one of the 36 states it names who will confirm the charge in writing before submitting an intake.
Visit VevaRXThe verdict
CoreAge Rx takes it, leading the Cost-Efficiency Index 94 to 60. Best value in the ranking: both molecules at one flat, all-50 price with no teaser step-ups — the lowest true cost of ownership, not the lowest teaser. VevaRX still earns a C — Readers in one of the 36 states it names who will confirm the charge in writing before submitting an intake.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | CoreAge Rx | VevaRX |
|---|---|---|
| Cost-Efficiency Index | 94/100 | 60/100 |
| Semaglutide / mo | $99/mo | $189/month month-to-month (the same page also prints $167/month and a $467 three-month total) |
| Tirzepatide / mo | $149/mo | $155.67/mo equivalent — VevaRX bills $467 every three months on a three-month minimum and publishes no monthly plan |
| Semaglutide / yr (modeled) | $1,188 | $2,268 |
| Tirzepatide / yr (modeled) | $1,788 | $1,860 |
| Coverage | All 50 states | 36 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #1 | #251 |
CoreAge Rx
94/100Where the value is
- Flat all-in monthly price — no intro rate that silently triples after month one, so the modeled annual cost is the real cost
- Both compounded semaglutide and tirzepatide on one account at published prices
- Available in all 50 states — no coverage gamble
The tradeoffs
- Not the rock-bottom sticker price — 30 of the 371 priced semaglutide programs we track list a cheaper figure, though most attach a term or a step-up that CoreAge does not
- No FDA-approved brand-name option (compounded only)
VevaRX
60/100Where the value is
- Enumerates the 36 states it serves by name rather than making an unqualified nationwide claim
- States what the tirzepatide price covers — the treatment, the supplies, the provider visit and two-to-three-day shipping
- Publishes a monthly semaglutide option alongside the quarterly plan, which its tirzepatide program does not offer
The tradeoffs
- The semaglutide page carries four prices, two of which belong to tirzepatide: $189 a month, $399 for three months, $167 a month and a $467 total
- The tirzepatide page's own arithmetic is wrong — it calls $467 over three months "equivalent to $149 per month", when it is $155.67, a figure the semaglutide page states correctly
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.